Skip to content

Advertisement

  • Poster presentation
  • Open Access

Serial monitoring of LV function following chemotherapy: assessment using advanced echocardiography and cardiovascular magnetic resonance

  • 1, 3,
  • 1, 2,
  • 1,
  • 2,
  • 4 and
  • 1, 3
Journal of Cardiovascular Magnetic Resonance201416 (Suppl 1) :P139

https://doi.org/10.1186/1532-429X-16-S1-P139

  • Published:

Keywords

  • Heart Failure
  • Breast Cancer Patient
  • Cardiovascular Magnetic Resonance
  • Cardiac Magnetic Resonance
  • Anthracyclines

Background

Patients receiving anthracyclines (A) and herceptin (H) for treatment of breast cancer require serial monitoring of LV function. Although CMR is considered the gold standard for assessment of volumes and function, most tertiary institutions rely on echocardiography or gated heart pool scans. 2D transthoracic echocardiographic (TTE) image quality relies on appropriate acoustic windows, and accuracy and reproducibility may be particularly limited in this population due to mastectomy and scar. We sought to assess the utility of TTE (LVEF and GLS) compared to CMR in the diagnosis of Stage B heart failure (defined as evidence of structural disease but without signs and symptoms of heart failure [1]) in breast cancer patients receiving cytotoxic chemotherapy.

Methods

In total, 44 patients (30 receiving A and 14 receiving T) underwent cardiac magnetic resonance (CMR) for LV function and advanced 2D echocardiography for LV function and global longitudinal strain (GLS) at 3 time-points (baseline, 3 months and 12 months). We defined stage B heart failure as LVEF < 10% from baseline, and/or LVEF below 55% and/or GLS < -19.7[2].

Results

CMR cine assessment of LV function was performed in all 44 patients (100%). Thirty percent (13/44) could not have accurate echocardiographic EF assessment performed at 1 or more time points. Early LV dysfunction was detected by CMR following commencement of chemotherapy (table). There was poor correlation between CMR LVEF and echocardiography EF (graph) with wide limits of agreement (-23.526 to 13.015%). At 12 months, 8 patients (18%) demonstrated stage B heart failure, however none were below the lower limits of normal (>55%). None of these showed a significant change in TTE EF, however 2 of these patients had GLS < 19.7 at 12 months.

Conclusions

A significant number (approx. 1/3) of breast cancer patients are unable to have adequate LV function assessment by echocardiography. Subtle LV dysfunction may be a precursor to overt cardiomyopathy and is currently not adequately diagnosed by echocardiography even with inclusion of 2D global longitudinal strain. Serial monitoring of LV function using a non-radiation imaging technique is best performed by CMR.

Funding

None.

Table 1

 

LVEF (CMR)

(%)

LVEF

(Echo)

(%)

GLS

Baseline

71.9 ± 6.3

63.8 ± 5.7

-21.4 ± 2.6

3 months

66.7 ± 6.7 **

63.5 ± 7.2

-19.5 ± 2.0 **

12 months

65.9 ± 7.0 **

62.1 ± .9

-20.1 ± 2.6

Figure 1

Authors’ Affiliations

(1)
Flinders University, Adelaide, South Australia, Australia
(2)
Cardiology, Flinders Medical Centre, Adelaide, South Australia, Australia
(3)
Flinders Cardiac Cardiovascular Magnetic Resonance, Flinders Medical Centre, Adelaide, South Australia, Australia
(4)
Medical Oncology, Flinders Centre for Innovation in Cancer, Adelaide, South Australia, Australia

References

  1. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG: 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009, 119 (14): e391-479.View ArticlePubMedGoogle Scholar
  2. Yingchoncharoen T, Agarwal S, Popovic ZB, Marwick TH: Normal ranges of left ventricular strain: a meta-analysis. J Am Soc Echocardiogr. 2013, 26 (2): 185-91. 10.1016/j.echo.2012.10.008.View ArticlePubMedGoogle Scholar

Copyright

© Grover et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement